GCLC

Across TCGA pan-cancer cohorts, GCLC Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated GCLC data layer compared with 23 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GCLC Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated GCLC expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

HNSC, UCEC, and LUAD are the cancer types where GCLC Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	All	0.157	0.687	.002	48	view →
UCEC	DFS	Median	II,III,IV	1.000	0.434	.008	30	view →
LUAD	OS	Median	II,III,IV	0.184	0.711	<.001	24	view →
COAD	OS	Median	All	0.575	0.872	.001	17	view →
SKCM	OS	Median	All	0.569	0.787	.004	9	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

GCLC–HNSC (OS)

Open the HNSC breakdown →